# Angiogenesis, Exudation, and Degeneration 2014





February 8, 2014

Bascom Palmer Eye Institute

Sponsored by the University of Miami Miller School of Medicine




UNIVERSITY OF MIAMI
MILLER SCHOOL
of MEDICINE

#### **BASCOM PALMER EYE INSTITUTE**

# Angiogenesis, Exudation, and Degeneration 2014

Bascom Palmer Eye Institute invites you to join us in February 2014 for our eleventh annual angiogenesis meeting. This unique and exciting symposium entitled *Angiogenesis*,



Exudation, and Degeneration 2014 will be held February 8, 2014 at the Mandarin Oriental Hotel in Miami, Florida. The meeting will feature an exceptional gathering of basic scientists, clinicians, and healthcare experts, all focused on understanding and treating neovascular and exudative diseases of the eye. The meeting will highlight the revolutionary pharmacotherapies now in development and clinical practice for the management of neovascular AMD, macular edema, diabetic retinopathy, and retinopathy of prematurity with a special emphasis on the present and future financial impact of these drugs on clinical practices and Medicare.



#### **COURSE CO-DIRECTORS**



Philip J. Rosenfeld, MD, PhD
Professor of Ophthalmology
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine
Course Co-Director, Angiogenesis 2014







Carmen A. Puliafito, MD, MBA
Dean, Keck School of Medicine
May S. and John Hooval Dean's Chair in Medicine
Professor of Ophthalmology and Health Management
Doheny Eye Institute
University of Southern California
Course Associate Director, Angiogenesis 2014

## **COURSE DESCRIPTION**

Angiogenesis 2014 follows the tradition of excellence established by the widely acclaimed Angiogenesis programs between 2004 and 2014. Designed for retinal specialists, general ophthalmologists and researchers, the current program will review the latest therapies for exudative eye diseases and the use of these new treatments in clinical practice. We will emphasize current and future treatments for a broad spectrum of retinal diseases with special emphasis on age-related macular degeneration and diabetic retinopathy.

#### **COURSE OBJECTIVES**

Upon completion of this program, participants should be able to:

- Enhance patient care by evaluating the current global use of anti-VEGF drugs for exudative ocular diseases
- Manage patients with anti-VEGF therapy through the preferred dosing practices
- Improve management skills by evaluating all the risks associated with injections of anti-VEGF drugs
- Analyze results of clinical trials in exudative macular diseases and apply to clinical practice
- Evaluate the benefits and limitations of combination therapies for exudative diseases
- Evaluate the benefits and limitations of different imaging strategies for age-related macular degeneration
- Enhance patient care by analyzing the genetic basis for different macular and retinal degenerative conditions
- Analyze the rationale for emerging treatments for different macular and retinal degenerative conditions
- Identify the types of stem cells and appreciate how they will be used to treat macular diseases

S

PI Si

7:0 7:5

8:0

8:2

8:

8:3

8:5

9:0

9:2

9:3

9:5

10

#### SATURDAY, FEBRUARY 8, 201

Registration and Continental Breakfast
Welcome and Overview Philip J. Rosenfeld, MD, PhD, Harry W. Flynn, Jr., MD, and Carmen A. Puliafito, MD, MBA
SESSION I – Dry Age-Related Macular Degeneration
Common and Rare Genetics of Macular Degeneration 2014: Paths to Treatment Johanna M. Seddon, MD, SCM
Toward a Refined Understanding of Genotype-Phenotype Associations in Age-related Macular Degeneration Gregory S. Hageman, PhD
Rehabilitating Lipofuscin as a Marker of RPE Health: Laboratory Autofluorescence Insights Christine A. Curcio, PhD, FARVO
AREDS2 Update Emily Y. Chew, MD
Two Color Microperimetry as an Endpoint for Dry Age- Related Macular Degeneration Trials: Present Status Karl G. Csaky, MD, PhD
Preclinical and Initial Clinic Results of Idebenone, A Ubuiqinone Analog for Dry AMD Scott W. Cousins, MD
Membrane Attack Complex (MAC), Protectin (CD59) and AMD Elias Reichel, MD
Anti-Factor D Therapy for Atrophic AMD: Phase II Clinical Trial Results Carl D. Regillo, MD, FACS
SESSION II: Stem Cells for Retinal Diseases
Application of iPS Cells to Retinal Diseases  Masayo Takahashi, MD, PhD
h-ESC Derived RPE Transplantation for Atrophic AMD Ninel Z. Gregori, MD
The California Project to Cure Blindness – An Update David R. Hinton, MD, FARVO
Subretinal Transplantation of Human Central Nervous System Stem Cells (HuCNS-SC) for the Treatment of Geographic Atrophy: Scientific Rationale and Study Design Theodore Leng, MD, MS
Microcatheter Delivery of Cell Therapy CNTO 2476 for Atrophic Age Related Macular Degeneration Allen C. Ho, MD

10:

10:2

10:3

10:4

11:0

11:1

11:2

11:4

11:5

12:0

12:1

12:2

12:3

1:20

1:30

10:10	The London Project - RPE Sheets for AMD Lyndon da Cruz, MD, MA, FRACO, FRCOpth, PhD	1:40
10:20	Stem Cell Based 3D Printing of Retina  Kang Zhang, MD, PhD	1:50
	SESSION III – Neovascular AMD: Conbercept Phase III Results	2:00
10:30	Moderator: Philip J. Rosenfeld, MD, PhD  Conbercept Development and Clinical Trials Peter K. Kaiser, MD	2:10
10:45	Treating Neovascular AMD by Using Conbercept: Preliminary Results from AURORA & PHOENIX Studies Xiaoxin Li, MD	2:20
11:00	Imaging Data from the Phase 3 Clinical Trial of Conbercept in Neovascular AMD	2:30
11:15	Ronald P. Danis, MD  Q&A/Discussion	2.40
	SESSION IV – Neovascular AMD	2:50
11:25	CATT and Beyond  Daniel F. Martin, MD	3:00
11:40	IVAN and Beyond Usha Chakravarthy, MD	3:10
11:55	Effect of Early, Persistent Macular Fluid on Visual Acuity in Wet AMD: Subgroup Analyses of the VIEW 1 VIEW 2 Studies Philip J. Rosenfeld MD, PhD	3:20
12:05 pm	Does Anti-VEGF Therapy Promote Geographic Atrophy in Exudative AMD?  Jason S. Slakter, MD	3:30
12:15	Dry Retinal Volume: Predicting Outcomes after Pharmacotherapy SriniVas R. Sadda, MD	
12:25	Systemic Safety of Anti-VEGF Therapy Robert L. Avery, MD	3:40
12:35	Lunch	
	SESSION IV – Neovascular AMD (continued)	3:50
1:20	Clinicopathologic Correlation of Eyes with Streptococcal Endophthalmitis Following Intravitreal Injections Sander R. Dubovy, MD	4:00
1:30	The Role of Genetics in Response to Anti-VEGF Therapy in Wet AMD Jaclyn L. Kovach, MD	

1:40	Immunoglobulins for CNV: Are Generics Just as Good?  Jayakrishna Ambati, MD	4:10
1:50	Pre-Clinical Investigations of Intravitreal Zaltrap  Michel E. Farah, MD	4:20
2:00	Results of the ROLL Study: Conversion of PEDs from 2mg Ranibizumab to 2mg Aflibercept Anne E. Fung, MD	4:30
2:10	Change in PED Volume Following the Switch from Bevacizumab/Ranibizumab to Aflibercept Mariana R. Thorell, MD	4:40
2:20	Update on Encapsulated Cell Technology for Wet AMD Glenn J. Jaffe, MD	4:50
2:30	Oral Anti-VEGF Therapy for Wet AMD  David M. Brown, MD, FACS	
2:40	Anti-VEGF Gene Therapy: Early Clinical Results Using the Ocular Biofactory in Wet AMD	5:00
2:50	Thomas W. Chalberg, PhD  Morphologic Correlation of Visual Outcome with  Anti-PDGF Combination Treatment in Exudative AMD  Pravin U. Dugel, MD	5:10
3:00	Stereotactic X-ray Radiotherapy for Neovascular AMD  Darius M. Moshfeghi, MD	5:20
3:10	Update on Treatment with Squalamine Eye Drops  Lawrence J. Singerman, MD, FACS, FICS	5:30
3:20	Integrin Antagonism in AMD and DME Hugo Quiroz-Mercado, MD	5:40
3:30	Inhibitor of Differentiation (Id) Proteins and Genes: A New Target for the Treatment of Posterior Segment Neovascularization	0.40
	Glenn L. Stoller, MD, FACS	5:50
	SESSION V – Vitreomacular, Retinovascular, and Choroidovascular Diseases	6:00
3:40	Current Clinical Trials for Hereditary Chorioretinal Degenerations Byron L. Lam, MD	
3:50	Multiple Evanescent White Dot Syndrome: Multimodal Imaging Lawrence A. Yannuzzi, MD	
4:00	A New, International Classification System and the Role of Ocriplasmin for Diseases of the Vitreomacular Interface Jay S. Duker, MD	

4:10	Ocriplasmin Safety and Side Effects
	Baruch D. Kuppermann, MD, PhD
4:20	Update on the MacTel Project and the Lowy Medical Research Institute: From Bench to Bedside in 8 Years Martin Friedlander, MD, PhD
4:30	Intravitreal Aflibercept for Macular Edema Due to Branch Retinal Vein Occlusion: 24 Week Results of the VIBRANT Study Jeffrey S. Heier, MD
4:40	Update on Aflibercept for Diabetic Macular Edema Diana V. Do, MD
4:50	Dexamethasone Intravitreal Implant for Diabetes: Result of the Phase 3 Trials David S. Boyer, MD
5:00	Update on the DRCR Network Studies Harry W. Flynn, Jr., MD
5:10	Treatment of Diabetic Macular Edema by Tie2 Activation with an Inhibitor of Vascular Endothelial-Protein Tyrosine Phosphatase Peter A. Campochiaro, MD
5:20	Interleukin-1-beta Inhibition in Proliferative Diabetic Retinopathy: Interim Analysis of a Clinical Pilot Study Stephan Michels, MD, MBA
5:30	Additional Pharmacologic Agents in Development for Diabetic Macular Edema <i>Quan Dong Nguyen, MD, MSc</i>
5:40	Non-Visible Non-Lethal Photocoagulation for Treatment of Macular Edema Employing the Arrhenius Calculation Mark S. Blumenkranz, MD
5:50	Peripheral Diabetic Retinopathy Diagnoses and Management Michael T. Trese, MD
6:00	Adjourn/Cocktail Reception



# Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2014

Saturday, February 8, 2014

Registration is limited, so please register early.

Last Name / First Name (as you want it to appear on name badge) / Degree
Last Four Digits of Social Security Number (for record keeping purposes only)
Specialty / Sub-specialty
Affiliated Institution
Address (Check box if new address)
City/State
Country / Zip or Postal Code
Office phone Office fax
Email
REGISTRATION: \$425
Enclosed is my check made payable to Bascom Palmer Eye Institute – Angiogenesis 2014
Please bill my credit card:
☐ Mastercard ☐ Visa ☐ American Express
Card number
Security code Expiration date Billing zip code
Name on card
Signature
By fax: Please complete this registration form with your credit cal

By fax: Please complete this registration form with your credit card payment and fax to (305) 326-6518. By mail: Please complete this registration form and return with your check or credit card payment to: Bascom Palmer Eye Institute

Continuing Medical Education Department 1120 NW 14th Street, Suite 1558 Miami, FL 33136

(Attn: Karen Davila)

#### **SPEAKERS**

#### Jayakrishna Ambati, MD

Professor and Vice Chair Dr. E Vernon Smith & Eloise C. Smith **Endowed Chair** Department of Ophthalmology & Visual Sciences University of Kentucky Lexington, KY

Robert L. Avery, MD Founder, California Retina Consultants Co-Founder, California Retina Research Foundation

Neuroscience Research Institute at UCSB Santa Barbara, CA

#### Mark S. Blumenkranz, MD

H.J. Smead Professor and Chairman Director, Byers Eye Institute at Stanford Stanford University School of Medicine Palo Alto, CA

David S. Boyer, MD
Clinical Professor of Ophthalmology Keck School of Medicine University of Southern California Retina-Vitreous Associates Medical Group Los Angeles, CA

## David M. Brown, MD, FACS

Clinical Associate Professor of Ophthalmology Weill Cornell Medical College The Methodist Hospital Retina Consultants of Houston Houston, TX

#### Peter A. Campochiaro, MD

George S. and Dolores Dore Eccles Professor of Ophthalmology and Neuroscience Wilmer Eye Institute The Johns Hopkins University School of Medicine

Baltimore, MD

#### Usha Chakravarthy, MD

Professor of Ophthalmology Queens University of Belfast Royal Victoria Hospital (The Belfast Trust) Northern Ireland, United Kingdom

Thomas W. Chalberg, PhD
President and Chief Executive Officer Avalanche Biotechnologies, Inc. San Francisco, CA

Emily Y. Chew, MD
Deputy Director, Division of Epidemiology & Clinical Applications Chief of Clinical Trials National Eye Institute Bethesda, MD

# Scott W. Cousins, MD Robert Machemer, MD, Professor of

Ophthalmology and Immunology Vice Chair for Research Director, Duke Center for Macular Diseases Duke Eye Center Duke University Durham, NC

Karl G. Csaky, MD, PhD T. Boone Pickens Senior Scientist Head, Harrington Molecular Laboratory Retina Foundation of the Southwest Dallas, TX

## Christine A. Curcio, PhD, FARVO

Professor of Ophthalmology Director, Age-related Maculopathy Histopathology Laboratory University of Alabama School of Medicine EyeSight Foundation Vision Research Labs Birmingham, AL

# Lyndon da Cruz, MD, MA, FRACO, FRCOpth, PhD

Consultant Ophthalmic Surgeon Moorfields Eye Hospital London, England

#### Ronald P. Danis, MD

Professor of Ophthalmology Director, UW-Madison Fundus Photograph Reading Center

University of Wisconsin Madison, WI

## Diana V. Do, MD Vice Chair for Education

Director of the Carl Camras Center for Innovative Clinical Trials in Ophthalmology Stanley M. Truhlsen Eye Institute University of Nebraska Medical Center Omaha, NE

#### Sander R. Dubovy, MD

Professor of Opthalmology Bascom Palmer Eye Institute University of Miami Miller School of Medicine Miami, FL

#### Pravin U. Dugel, MD

Clinical Associate Professor of Ophthalmology Keck School of Medicine University of Southern California Los Angeles, CA Managing Partner

Retina Consultants of Arizona Phoenix, AZ

Jay S. Duker, MD Professor and Chairman

Director, New England Eye Center Tufts Medical Center Tufts University School of Medicine Boston, MA

## Michel E. Farah, MD

Professor of Ophthalmology President, Vision Institute Paulista School of Medicine São Paulo Federal University

São Paulo, Brazil Martin Friedlander, MD, PhD Professor, Department of Cell and Molecular Biology

Chief, Retina Services, Division of Ophthalmology, Department of Surgery The Scripps Research Institute Scripps Clinic

La Jolla, CA

# Anne E. Fung, MD California Pacific Medical Center

Pacific Eye Associates San Francisco, CA

#### Ninel Z. Gregori, MD

Associate Professor of Clinical Opthalmology Bascom Palmer Eye Institute University of Miami Miller School of Medicine Miami, FL

# Gregory S. Hageman, PhD John A. Moran Presidential Professor

Executive Director, Moran Center for Translational Medicine John A. Moran Eye Center University of Utah Salt Lake City, UT

Jeffrey S. Heier, MD Director, Vitreo-Retina Service Ophthalmic Consultants of Boston Boston, MA

**David R. Hinton, MD, FARVO**Professor of Pathology and Ophthalmology
Gavin S. Herbert Professor of Retinal Research Associate Dean of Vision Science Vice Chair, Department of Pathology

Keck School of Medicine University of Southern California Los Angeles, CA

t card ete this ment to:

ıly)

4

SS

RACO,

graph

r er

/ledicine

almology

mology

gery

lmology

/ledicine

nology

Allen C. Ho, MD

Professor of Ophthalmology Director, Retina Research Wills Eye Hospital Thomas Jefferson University Mid Atlantic Retina Philadelphia, PA

Glenn J. Jaffe, MD Professor of Ophthalmology Chief, Vitreoretinal Service Director, Duke Reading Center Duke Eye Center Duke University School of Medicine Durham, NC

Peter K. Kaiser, MD Professor of Ophthalmology

Chaney Family Endowed Chair for Ophthalmology Research Cleveland Clinic Lerner College of Medicine Cole Eye Institute Cleveland, OH

Jaclyn L. Kovach, MD
Assistant Professor of Clinical Ophthalmology
Bascom Palmer Eye Institute Retina Center at Naples University of Miami Miller School of Medicine Naples, FL

Baruch D. Kuppermann, MD, PhD Professor of Ophthalmology and

Biomedical Engineering Chief, Retina Service Vice Chair, Clinical Research The Gavin Herbert Eye Institute University of California, Irvine Irvine, CA

Byron L. Lam. MD

Professor of Opthalmology Bascom Palmer Eye Institute University of Miami Miller School of Medicine Miami, FL

Theodore Leng, MD, MS Clinical Assistant Professor of Ophthalmology Byers Eye Institute at Stanford Stanford University School of Medicine Palo Alto, CA

Xiaoxin Li, MD Professor and Chair

Eye Center of People's Hospital Peking University

Beijing, China

Daniel F. Martin, MD Barbara and A. Malachi Mixon III Institute

Chair in Ophthalmology Chairman Cole Eye Institute Cleveland Clinic Cleveland, OH

Stephan Michels, MD, MBA Associate Professor of Ophthalmology Head, Medical Retina Triemli Hospital Zurich Zurich, Switzerland

Darius M. Moshfeghi, MD

Associate Professor Byers Eye Institute at Stanford Stanford University School of Medicine Palo Alto, CA

Quan Dong Nguyen, MD, MSc Professor and Chairman Director of the Stanley M. Truhlsen Eye Institute McGaw Memorial Endowed Chair in Ophthalmology University of Nebraska Medical Center Omaha, NE

Hugo Quiroz-Mercado, MD Professor of Ophthalmology

University of Colorado School of Medicine Denver, CO

Carl D. Regillo, MD, FACS

Professor of Ophthalmology Director, Retina Service Wills Eye Institute Thomas Jefferson University Philadelphia, PA

Elias Reichel, MD

Professor and Vice Chair of Ophthalmology Director, Vitreoretinal Service New England Eye Center Tufts Medical Center Tufts University School of Medicine Boston, MA

i

SriniVas R. Sadda, MD

Professor of Ophthalmology Keck School of Medicine University of Southern California Los Angeles, CA

Johanna M. Seddon, MD, SCM

Professor of Ophthalmology
Founding Director, Ophthalmic Epidemiology and Genetics Service New England Eye Center Tufts Medical Center Tufts University School of Medicine Boston, MA

Lawrence J. Singerman, MD, FACS, FICS

Clinical Professor of Ophthalmology Case Western Reserve University Retina Associates of Cleveland, Inc. Beachwood, OH Voluntary Professor of Ophthalmology Bascom Palmer Eye Institute
University of Miami Miller School of Medicine

Jason S. Slakter, MD Clinical Professor of Ophthalmology New York University School of Medicine Partner, Vitreous-Retina Macula Consultants of New York New York, NY

Glenn L. Stoller, MD, FACS Ophthalmic Consultants of Long Island

Rockville Center, NY Masayo Takahashi, MD, PhD

RIKEN Center for Developmental Biology (CDB) Chuo-ku, Kobe, Japan

Mariana R. Thorell, MD

Post Doctoral Associate Bascom Palmer Eye Institute University of Miami Miller School of Medicine Miami, FL

Michael T. Trese, MD Clinical Professor of Ophthalmology Chief of Pediatric & Adult Vitreoretinal Surgery William Beaumont Hospital Oakland University William Beaumont School of Medicine

Associated Retinal Consultants Royal Oak, MI

Lawrence A. Yannuzzi, MD Professor of Clinical Ophthalmology

Columbia University School of Medicine Founder and Director, LuEsther T. Mertz Retinal Research Center and Macula Foundation, Inc. New York, NY

Kang Zhang, MD, PhD

Professor of Ophthalmology and Human Genetics Founding Director, UCSD Institute for Genomic Medicine University of California San Diego La Jolla, CA

# Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2014

## DATE

Saturday, February 8, 2014: 7:55 am to 5:30 pm

## **LOCATION**

## Mandarin Oriental, Miami

500 Brickell Key Drive, Miami, FL 33131

Reservations: (800) 526-6566 Direct: (305) 913-8288

Mandarin Oriental, Miami is one of America's finest hotels and recently awarded the AAA Five Diamond Award. Ideally located on prestigious Brickell Key, its deluxe, waterfront location perfectly befits the opulence you'll find within. The rooms are luxurious, the award-winning restaurants are some of the finest in Miami and the spa is one of the most beautiful in the world. The hotel's extensive leisure facilities make it the perfect choice for a conference or a holiday in Miami.

#### **HOTEL RESERVATIONS**

For hotel information and reservations, please call (305) 913-8288 or (800) 526-6566.

The special hotel rate for conference attendees is \$379 per night for single or double plus tax. Mandarin Oriental, Miami will extend the special group rate for three days prior and three days after the main program dates, subject to availability. Check-in time is 3:00 pm; Check-out time is 12:00 noon.

We suggest you make your hotel reservations as soon as possible as the winter months are the height of South Florida's tourist season. Bascom Palmer's preferred room rate will be released after January 8, 2014. Reservations and deposits received after that time are subject to current rates and availability. Please contact the Mandarin Oriental Miami for hotel cancellation policies. For additional information visit: www.mandarinoriental.com/miami

## **CONFERENCE FEES**

Registration rate is \$425.

Conference fees include course materials, opening reception, continental breakfast, lunch and refreshment breaks.

#### **CANCELLATION POLICY**

Conference tuition, less \$100 cancellation fee, is refundable if notice is received on or before January 8, 2014. Cancellations received on or after January 9, 2014 will not be refunded.

gy

ne

nts

DB)

gery

ne

etinal Inc.

#### **ACCREDITATION**

University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

#### **CREDIT DESIGNATION**

The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of *9.25 AMA PRA Category 1 Credits.*™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

#### **DISCLOSURE AND CONFLICT OF INTEREST RESOLUTION**

All conflicts of interest of any individual in a position to control the content of this CME activity will be identified and resolved prior to this educational activity being provided. Disclosure about provider and faculty relationships, or the lack thereof, will be provided to learners.

#### SERVICES FOR THE DISABLED

If special arrangements are required for an individual with a disability to attend this conference, please contact Karen Davila at (305) 326-6110 on or before January 15, 2014.

**REGISTRATION** Space is limited. Please register early. **To register by mail:** Please complete the registration form and return with your check or credit card payment to:

Bascom Palmer Eye Institute

Department of Continuing Medical Education 1120 NW 14th Street, Suite 1558, Miami, FL 33136 (Att: Karen Davila)

**To register by fax:** Please complete the registration form and return with your credit card payment to (305) 326-6518.

## For more information contact:

Bascom Palmer Eye Institute
Department of Continuing Medical Education
at (305) 326-6110 / Email: bascompalmercme@miami.edu



